Telo Genomics Corp (TELO) AI Stock Analysis

• Market Cap: C$5.02M
• Dividend Yield: N/A
• Average Volume (3M): 29.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: N/A
• EPS Growth: 19.05%
• Country: CA
• Employees: 8
• Sector: N/A
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 100,430,470
• 10 Day Avg. Volume: 22,350
• 30 Day Avg. Volume: 29,304
• PEG Ratio: 0.19
• Price to Book (P/B): 18.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 28 Underperform
• Price Target: ―

Telo Genomics Corp's stock is rated low due to significant financial challenges, including no revenue and persistent losses, which overshadow the positive corporate developments. The bearish technical indicators and valuation concerns further contribute to the low score. Despite recent strategic initiatives, the company's current financial instability poses a high risk to investors.

Telo Genomics Corp Business Overview & Revenue Model

Company Description

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

How the Company Makes Money

Telo Genomics Corp generates revenue primarily through the commercialization of its genomic testing products and services. The company offers diagnostic tests that are used in clinical settings to aid in the detection and monitoring of diseases. Revenue streams include sales of test kits, laboratory services, and potentially licensing agreements for its proprietary technologies. Partnerships with healthcare providers, research institutions, and pharmaceutical companies are significant contributors to its earnings, allowing for broader distribution and integration of its genomic solutions into medical practice.

Telo Genomics Corp Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Telo Genomics Corp Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Neutral. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.25 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:TELO.

Telo Genomics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	―	―	―	―	―	―
AVCR	64 Neutral	C$5.57M	-3.11	-71.97%	―	-59.28%	-1563.64%
BUX	58 Neutral	C$51.49M	-27.16	―	―	-21.89%	26.36%
IZO	37 Underperform	C$19.65M	-7.80	40.96%	―	―	11.68%
TELO	28 Underperform	C$5.02M	-1.73	-9999.00%	―	―	19.05%

Telo Genomics Corp Corporate Events

Telo Genomics’ MRD Data in Multiple Myeloma Gains ASCO Recognition

Telo Genomics Corp announced the acceptance of its abstract on Minimal Residual Disease (MRD) validation data in multiple myeloma by the American Society of Clinical Oncology (ASCO) for online publication at their 2025 Annual Meeting. This recognition underscores the significance of Telo’s TeloView® technology in assessing MRD, which is crucial for monitoring myeloma post-transplantation. The company’s ongoing clinical trials aim to develop prognostic tests that could revolutionize precision medicine by providing actionable insights for clinicians. The acceptance by ASCO, a prestigious oncology conference, highlights the potential impact of Telo’s innovations on the treatment and management of multiple myeloma, a challenging blood cancer.

Spark’s Take on TSE:TELO Stock

According to Spark, TipRanks’ AI Analyst, TSE:TELO is a Underperform.

Telo Genomics Corp faces substantial financial challenges, with no revenue and persistent losses being significant risks. The technical analysis indicates a bearish trend, while the negative P/E ratio underscores valuation concerns. Recent corporate events provide some optimism for future operational improvements, but these have yet to translate into financial stability. Overall, the stock is high-risk, with potential upside if strategic initiatives succeed.

To see Spark’s full report on TSE:TELO stock, click here.

Telo Genomics Strengthens Leadership with New Board Appointment

Telo Genomics Corp. has appointed John Farlinger to its Board of Directors, where he will also serve as Chair of the audit committee. Farlinger brings over 30 years of experience in telecom, operations, technology, and finance, which is expected to bolster Telo Genomics’ strategic leadership and support its growth phase. Additionally, the company has granted stock options to Farlinger and a strategic consultant, reflecting its commitment to aligning incentives with its development goals. This move is anticipated to enhance Telo Genomics’ operational capabilities and strengthen its market position in the biotech industry.

Telo Genomics Strengthens Leadership with New Executive Chairman

Telo Genomics Corp has appointed Guido Baechler as the Executive Chairman of its Board of Directors, enhancing his role to provide strategic leadership in advancing the company’s machine-learning-driven 3D Telomere platform in oncology. This move is expected to support the company’s growth and commercialization efforts, particularly in the areas of multiple myeloma and prostate cancer. The company also announced stock option grants to insiders, employees, and consultants, and reported changes in its board and management team.

Telo Genomics Expands Partnership with Trusted Health Advisors for Diagnostic Advancements

Telo Genomics Corp has expanded its partnership with Trusted Health Advisors to enhance the commercialization of its diagnostic technologies over a six-month period. This collaboration will support various clinical programs, including those targeting multiple myeloma and prostate cancer, and involves the establishment of a clinical advisory board and collaboration with academic partners and reference labs. The partnership aims to advance Telo’s market positioning in oncology diagnostics by leveraging the expertise of THA’s experienced team.